Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Prices $250M Public Stock Offering

NEW YORK – Quanterix said on Thursday that it has priced a public offering of 3,571,428 shares of its common stock at $70.00 per share. The Billerica, Massachusetts-based firm expects gross proceeds of around $250 million from the offering, which it announced on Wednesday.

The company has granted the underwriters a 30-day option to purchase up to an additional 535,714 shares of common stock at the public offering price less underwriting discounts, commissions, and offering expenses.

Goldman Sachs, SVB Leerink, and Cowen are the joint bookrunning managers for the offering, and Canaccord Genuity is the lead manager.

The offering is expected to close on Feb. 8.

Last month, Quanterix received Emergency Use Authorization from the US Food and Drug Administration for its Simoa SARS-CoV-2 N Protein Antigen Test.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.